Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today announced that the Company will be participating in three upcoming virtual investor conferences:
Morgan Stanley Virtual 19th Annual Global Healthcare Conference
Fireside Chat Date: Friday, September 10, 2021
Time: 2:00 PM ET
H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13th through Wednesday, September 15th, 2021
Oppenheimer’s Virtual Fall Healthcare Life Sciences & MedTech Summit
Presentation Date: Wednesday, September 22, 2021
Time: 3:45 PM ET
The fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference and presentation at the Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit will be webcast live. A pre-recorded webcast of the presentation at the H.C. Wainwright 23rd Annual Global Investment Conference will be made available on Monday, September 13, 2021, at 7:00 AM ET. All of the webcasts can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay of each webcast will also be available.
About Vor Biopharma
Vor Biopharma is a cell and genome engineering company that aims to transform the lives of cancer patients by pioneering an engineered hematopoietic stem cell (eHSC) therapeutic platform that unlocks the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancer cells while sparing healthy cells.
Contacts:
Investors:
Chris Brinzey
Westwicke, an ICR Company
+1 339-970-2843
chris.brinzey@westwicke.com
Media:
Rebecca Spalding
Ten Bridge Communications
+1 646-509-3831
rebecca@tenbridgecommunications.com
| Last Trade: | US$0.16 |
| Daily Change: | -0.38 -70.12 |
| Daily Volume: | 16,358,029 |
| Market Cap: | US$19.930M |
March 20, 2025 January 08, 2025 December 27, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
